Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 7/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402470 | 0.92 | BDKRB1 (0.43) | BDKRB1MCOLN3CNR1CNR2CDK8 | |
| SCHEMBL5396899 | 0.90 | BDKRB1 (0.44) | BDKRB1MCOLN3CNR1CNR2CDK8 | |
| SCHEMBL5393047 | 0.90 | BDKRB1 (0.41) | BDKRB1MCOLN3CNR1CNR2PTGDR2 | |
| SCHEMBL5383630 | 0.90 | BDKRB1 (0.41) | BDKRB1MCOLN3CNR1CNR2TSHR | |
| SCHEMBL5393673 | 0.89 | BDKRB1 (0.43) | BDKRB1MCOLN3CNR1CNR2LTB4R | |
| SCHEMBL5390403 | 0.89 | BDKRB1 (0.41) | BDKRB1MCOLN3CNR1CNR2LTB4R2 | |
| SCHEMBL5385479 | 0.88 | BDKRB1 (0.41) | BDKRB1MCOLN3CNR1CNR2TSHR | |
| SCHEMBL5393895 | 0.88 | MCOLN3 (0.43) | BDKRB1MCOLN3CNR1CNR2LTB4R2 | |
| SCHEMBL5388713 | 0.87 | BDKRB1 (0.40) | BDKRB1MCOLN3CNR1CNR2 | |
| SCHEMBL5392217 | 0.87 | BDKRB1 (0.42) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | BDKRB1 1/4885MCOLN3 1853/4885CNR1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.